Ascendis Pharma Stock (NASDAQ:ASND)
Previous Close
$124.44
52W Range
$90.13 - $161.00
50D Avg
$132.40
200D Avg
$137.02
Market Cap
$7.43B
Avg Vol (3M)
$642.62K
Beta
0.65
Div Yield
-
ASND Company Profile
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
ASND Performance
Peer Comparison
| Ticker | Company |
|---|---|
| DICE | DICE Therapeutics, Inc. |
| PLRX | Pliant Therapeutics, Inc. |
| NUVL | Nuvalent, Inc. |
| AKRO | Akero Therapeutics, Inc. |
| APLS | Apellis Pharmaceuticals, Inc. |
| BPMC | Blueprint Medicines Corporation |
| DAWN | Day One Biopharmaceuticals, Inc. |
| VTYX | Ventyx Biosciences, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| BGNE | BeiGene, Ltd. |
| REPL | Replimune Group, Inc. |
| KDNY | Chinook Therapeutics, Inc. |
| CRNX | Crinetics Pharmaceuticals, Inc. |
| ACLX | Arcellx, Inc. |
| ETNB | 89bio, Inc. |
| UTHR | United Therapeutics Corporation |
| KRTX | Karuna Therapeutics, Inc. |
| MDGL | Madrigal Pharmaceuticals, Inc. |
| AMLX | Amylyx Pharmaceuticals, Inc. |